Sep 12, 2025
BioDlink commends junshi on JS212's IND approval
BioDlink, a leading global CDMO, extends its congratulations to Junshi Biosciences (HKEX-1877; SSE-688180), on receiving Investigational New Drug (IND) approval from China’s National Medical Products Administration (NMPA) for JS212, a bispecific antibody-drug conjugate (ADC) designed to target both EGFR and HER3 receptors. JS212 represents a new class of bispecific ADCs that combine the humanized…
View On WordPress